WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100667
Description: Nilutamide is an antiandrogen medication used in the treatment of advanced-stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. Because most prostate cancer cells rely on the stimulation of the androgen receptor for growth and survival, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States and under the name Anandron in Canada. (Source: http://en.wikipedia.org/wiki/Nilutamide)
MedKoo Cat#: 100667
Chemical Formula: C12H10F3N3O4
Exact Mass: 317.06234
Molecular Weight: 317.22071
Elemental Analysis: C, 45.43; H, 3.18; F, 17.97; N, 13.25; O, 20.17
Nilutamide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: NILANDRON 55dimethyl34nitro3(trifluoromethyl)phenyl24imidazolidinedione
IUPAC/Chemical Name: 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
InChi Key: XWXYUMMDTVBTOU-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
SMILES Code: O=C1N(C2=CC=C([N+]([O-])=O)C(C(F)(F)F)=C2)C(C(C)(C)N1)=O
The following data is based on the product molecular weight 317.22071 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Norlin M, Pettersson H, Tang W, Wikvall K. Androgen receptor-mediated regulation of the anti-atherogenic enzyme CYP27A1 involves the JNK/c-jun pathway. Arch Biochem Biophys. 2010 Dec 4. [Epub ahead of print] PubMed PMID: 21134350.
2: Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011 Jan;102(1):51-6. doi: 10.1111/j.1349-7006.2010.01774.x. Epub 2010 Nov 22. PubMed PMID: 21091846.
3: Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2010 Sep 28. [Epub ahead of print] PubMed PMID: 20878947.
4: Pavone-Macaluso M. Words of wisdom. Re: Does oral antiandrogen use before leuteinizing hormone-releasing therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Oh WK, Landrum MB, Lamont EB, et al. Urology 2010;75:642-7. Eur Urol. 2010 Aug;58(2):314-5. PubMed PMID: 20845534.
5: Keiser J, Vargas M, Vennerstrom JL. Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. J Antimicrob Chemother. 2010 Sep;65(9):1991-5. Epub 2010 Jun 24. PubMed PMID: 20576641; PubMed Central PMCID: PMC2920177.
6: Labrie F. Hormonal therapy of prostate cancer. Prog Brain Res. 2010;182:321-41. PubMed PMID: 20541672.
7: Koizumi H, Yu J, Hashimoto R, Ouchi Y, Okabe T. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Lett. 2010 Jun 3;584(11):2440-4. Epub 2010 Apr 21. PubMed PMID: 20416296.
8: Yu J, Akishita M, Eto M, Ogawa S, Son BK, Kato S, Ouchi Y, Okabe T. Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. Endocrinology. 2010 Apr;151(4):1822-8. Epub 2010 Mar 1. PubMed PMID: 20194727.
9: Langenhuijsen JF, van Lin EN, Hoffmann AL, Spitters-Post I, Alfred Witjes J, Kaanders JH, Mulders PF. Neoadjuvant androgen deprivation for prostate volume reduction: The optimal duration in prostate cancer radiotherapy. Urol Oncol. 2011 Jan-Feb;29(1):52-7. Epub 2009 Jun 12. PubMed PMID: 19523856.
10: Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):983-9. Epub 2009 May 4. PubMed PMID: 19409726.
Nilutamide is an antiandrogen medication used in the treatment of advanced stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. Because most prostate cancer cells rely on the stimulation of the androgen receptor for growth and survival, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States and under the name Anandron in Canada.
NILANDRONÂ® tablets contain nilutamide, a nonsteroidal, orally active antiandrogen having the chemical name 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione. Nilutamide is a microcrystalline, white to practically white powder with a molecular weight of 317.25. Its molecular formula is C12H10F3N3O4. It is freely soluble in ethyl acetate, acetone, chloroform, ethyl alcohol, dichloromethane, and methanol. It is slightly soluble in water [ < 0.1% W/V at 25Â°C (77Â°F)]. It melts between 153Â°C and 156Â°C (307.4Â°F and 312.8Â°F). Each NILANDRON tablet contains 150 mg of nilutamide. Other ingredients in NILANDRON tablets are corn starch, lactose, povidone, docusate sodium, magnesium stearate, and talc.
Mechanism of Action: Prostate cancer is known to be androgen sensitive and responds to androgen ablation. In animal studies, nilutamide has demonstrated antiandrogenic activity without other hormonal (estrogen, progesterone, mineralocorticoid, and glucocorticoid) effects. In vitro, nilutamide blocks the effects of testosterone at the androgen receptor level. In vivo, nilutamide interacts with the androgen receptor and prevents the normal androgenic response.